 Amrut Ambardekar
Concepts (430)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 38 | 2025 | 552 | 8.220 |
Why?
| | Heart Failure | 53 | 2025 | 2236 | 6.200 |
Why?
| | Heart Transplantation | 24 | 2024 | 754 | 4.770 |
Why?
| | Cardiomyopathies | 10 | 2025 | 350 | 1.890 |
Why?
| | Amyloidosis | 4 | 2023 | 42 | 1.780 |
Why?
| | Heart Ventricles | 9 | 2020 | 788 | 1.570 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 385 | 1.090 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 382 | 1.050 |
Why?
| | Myocytes, Cardiac | 13 | 2025 | 526 | 1.030 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2024 | 142 | 0.960 |
Why?
| | Myocardium | 10 | 2023 | 1002 | 0.930 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 333 | 0.840 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 238 | 0.820 |
Why?
| | Humans | 104 | 2025 | 137585 | 0.820 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 315 | 0.790 |
Why?
| | Rejuvenation | 1 | 2022 | 19 | 0.770 |
Why?
| | Assisted Circulation | 2 | 2021 | 26 | 0.760 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 47 | 0.750 |
Why?
| | Transplant Recipients | 4 | 2021 | 184 | 0.730 |
Why?
| | Echocardiography | 7 | 2017 | 642 | 0.730 |
Why?
| | Fibrosis | 5 | 2022 | 552 | 0.730 |
Why?
| | Hemodynamics | 7 | 2023 | 1113 | 0.710 |
Why?
| | Stroke Volume | 9 | 2024 | 612 | 0.710 |
Why?
| | Amyloid Neuropathies, Familial | 3 | 2025 | 16 | 0.700 |
Why?
| | Vascular Stiffness | 2 | 2017 | 494 | 0.690 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 72 | 0.690 |
Why?
| | Giant Cells | 1 | 2020 | 24 | 0.690 |
Why?
| | Arteries | 1 | 2022 | 269 | 0.670 |
Why?
| | Aortic Diseases | 1 | 2021 | 119 | 0.660 |
Why?
| | Heart Neoplasms | 1 | 2020 | 50 | 0.660 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 890 | 0.650 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 534 | 0.650 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 81 | 0.650 |
Why?
| | Myocarditis | 1 | 2020 | 100 | 0.620 |
Why?
| | Coronary Vessels | 2 | 2018 | 248 | 0.620 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 285 | 0.610 |
Why?
| | Middle Aged | 37 | 2025 | 33479 | 0.600 |
Why?
| | Brugada Syndrome | 2 | 2009 | 10 | 0.590 |
Why?
| | Myocardial Contraction | 4 | 2020 | 341 | 0.580 |
Why?
| | Graft Rejection | 3 | 2021 | 624 | 0.580 |
Why?
| | Ventricular Remodeling | 4 | 2025 | 266 | 0.570 |
Why?
| | Heart | 6 | 2023 | 655 | 0.570 |
Why?
| | Male | 51 | 2025 | 67762 | 0.560 |
Why?
| | Extracellular Matrix | 1 | 2021 | 528 | 0.540 |
Why?
| | Bariatric Surgery | 1 | 2021 | 217 | 0.540 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 263 | 0.520 |
Why?
| | Female | 49 | 2025 | 73304 | 0.490 |
Why?
| | Cryosurgery | 1 | 2016 | 59 | 0.480 |
Why?
| | Heart Rate | 2 | 2021 | 822 | 0.470 |
Why?
| | Thrombosis | 2 | 2016 | 371 | 0.470 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 259 | 0.440 |
Why?
| | Aged | 23 | 2025 | 23961 | 0.440 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 175 | 0.440 |
Why?
| | Blood Pressure | 5 | 2022 | 1786 | 0.420 |
Why?
| | Electrocardiography | 4 | 2020 | 629 | 0.420 |
Why?
| | Marijuana Abuse | 1 | 2016 | 233 | 0.410 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 267 | 0.400 |
Why?
| | Treatment Outcome | 13 | 2024 | 10811 | 0.390 |
Why?
| | Prealbumin | 4 | 2025 | 30 | 0.390 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 548 | 0.390 |
Why?
| | Myofibrils | 3 | 2022 | 50 | 0.390 |
Why?
| | Patient-Centered Care | 2 | 2021 | 530 | 0.380 |
Why?
| | Guideline Adherence | 3 | 2011 | 556 | 0.350 |
Why?
| | Adult | 21 | 2023 | 37929 | 0.340 |
Why?
| | Patient Compliance | 2 | 2017 | 581 | 0.340 |
Why?
| | Cardiology | 2 | 2023 | 274 | 0.340 |
Why?
| | Recovery of Function | 2 | 2011 | 653 | 0.330 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 12 | 0.330 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 181 | 0.320 |
Why?
| | Calcium | 4 | 2023 | 1199 | 0.320 |
Why?
| | Hospitals, Rural | 1 | 2009 | 39 | 0.320 |
Why?
| | Risk Assessment | 6 | 2021 | 3457 | 0.320 |
Why?
| | Baroreflex | 2 | 2021 | 57 | 0.320 |
Why?
| | Sarcomeres | 3 | 2022 | 96 | 0.320 |
Why?
| | Cardiac Output | 3 | 2023 | 165 | 0.310 |
Why?
| | Safety | 1 | 2011 | 338 | 0.310 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 81 | 0.310 |
Why?
| | Hospitals, Urban | 1 | 2009 | 134 | 0.310 |
Why?
| | Automobile Driving | 1 | 2011 | 148 | 0.310 |
Why?
| | Cannabis | 1 | 2016 | 494 | 0.300 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 87 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.300 |
Why?
| | Registries | 6 | 2021 | 2035 | 0.300 |
Why?
| | Pulsatile Flow | 2 | 2018 | 60 | 0.290 |
Why?
| | Mastitis | 1 | 2007 | 5 | 0.280 |
Why?
| | Counseling | 1 | 2011 | 391 | 0.280 |
Why?
| | Vascular Remodeling | 2 | 2021 | 193 | 0.280 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 54 | 0.280 |
Why?
| | Puerperal Disorders | 1 | 2007 | 31 | 0.280 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1483 | 0.270 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 322 | 0.270 |
Why?
| | Coronary Disease | 1 | 2009 | 385 | 0.270 |
Why?
| | Length of Stay | 2 | 2009 | 1215 | 0.260 |
Why?
| | Environment | 1 | 2009 | 358 | 0.260 |
Why?
| | Prospective Studies | 10 | 2021 | 7604 | 0.260 |
Why?
| | Diastole | 2 | 2018 | 149 | 0.250 |
Why?
| | Retrospective Studies | 13 | 2023 | 15657 | 0.250 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5131 | 0.240 |
Why?
| | HIV Infections | 1 | 2020 | 2836 | 0.240 |
Why?
| | Troponin I | 2 | 2019 | 81 | 0.240 |
Why?
| | Inpatients | 1 | 2009 | 500 | 0.230 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2025 | 36 | 0.230 |
Why?
| | Heart Failure, Systolic | 2 | 2024 | 25 | 0.230 |
Why?
| | Quality of Health Care | 1 | 2009 | 642 | 0.220 |
Why?
| | Methyltransferases | 1 | 2025 | 78 | 0.220 |
Why?
| | Quality of Life | 6 | 2024 | 2892 | 0.210 |
Why?
| | Perioperative Care | 2 | 2017 | 178 | 0.210 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 10 | 0.210 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 38 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 37 | 0.200 |
Why?
| | Preoperative Care | 2 | 2017 | 362 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2189 | 0.200 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 43 | 0.200 |
Why?
| | MicroRNAs | 2 | 2022 | 692 | 0.200 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 257 | 0.200 |
Why?
| | Patient Transfer | 2 | 2019 | 176 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 92 | 0.190 |
Why?
| | Metalloproteases | 1 | 2022 | 43 | 0.190 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 14 | 0.190 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 452 | 0.190 |
Why?
| | Hospitalization | 4 | 2024 | 2199 | 0.190 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.190 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.190 |
Why?
| | Cohort Studies | 6 | 2023 | 5742 | 0.190 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.190 |
Why?
| | Succinic Acid | 2 | 2019 | 37 | 0.190 |
Why?
| | Triage | 1 | 2024 | 222 | 0.190 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 17 | 0.180 |
Why?
| | Leukopenia | 1 | 2021 | 31 | 0.180 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 134 | 0.180 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.180 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 218 | 0.180 |
Why?
| | Mice | 13 | 2025 | 17787 | 0.180 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.170 |
Why?
| | Prognosis | 5 | 2025 | 4030 | 0.170 |
Why?
| | Muscle Proteins | 1 | 2022 | 231 | 0.170 |
Why?
| | Carrier Proteins | 2 | 2022 | 771 | 0.170 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 117 | 0.170 |
Why?
| | Case-Control Studies | 4 | 2022 | 3556 | 0.170 |
Why?
| | Alternative Splicing | 1 | 2022 | 229 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 660 | 0.170 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1046 | 0.170 |
Why?
| | Cell Adhesion | 2 | 2018 | 466 | 0.170 |
Why?
| | Transcriptome | 3 | 2025 | 971 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1295 | 0.160 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1738 | 0.160 |
Why?
| | HIV | 1 | 2020 | 234 | 0.150 |
Why?
| | Disease Progression | 2 | 2018 | 2757 | 0.150 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 135 | 0.150 |
Why?
| | Terminology as Topic | 1 | 2020 | 216 | 0.150 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 278 | 0.150 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2828 | 0.150 |
Why?
| | Aortic Valve | 1 | 2022 | 351 | 0.150 |
Why?
| | Consensus | 4 | 2023 | 683 | 0.150 |
Why?
| | Animals | 16 | 2025 | 36940 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 363 | 0.150 |
Why?
| | United States | 9 | 2023 | 14841 | 0.150 |
Why?
| | Exercise Test | 4 | 2023 | 625 | 0.150 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 180 | 0.150 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2844 | 0.140 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 322 | 0.140 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 243 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 248 | 0.140 |
Why?
| | Filamins | 1 | 2018 | 28 | 0.140 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 188 | 0.140 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 257 | 0.140 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 13 | 0.130 |
Why?
| | Recurrence | 1 | 2020 | 1060 | 0.130 |
Why?
| | Mutation | 2 | 2018 | 3958 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 268 | 0.130 |
Why?
| | Pilot Projects | 3 | 2019 | 1710 | 0.130 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 20 | 0.130 |
Why?
| | Brain | 2 | 2018 | 2668 | 0.130 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 167 | 0.130 |
Why?
| | ErbB Receptors | 1 | 2020 | 614 | 0.130 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 243 | 0.130 |
Why?
| | Down-Regulation | 2 | 2016 | 657 | 0.130 |
Why?
| | Anesthetics | 1 | 2017 | 81 | 0.130 |
Why?
| | Time Factors | 5 | 2024 | 6828 | 0.130 |
Why?
| | Self Care | 1 | 2019 | 380 | 0.130 |
Why?
| | Histone Deacetylases | 1 | 2018 | 215 | 0.130 |
Why?
| | Polypharmacy | 1 | 2017 | 85 | 0.130 |
Why?
| | Transition to Adult Care | 1 | 2017 | 91 | 0.120 |
Why?
| | Eligibility Determination | 1 | 2016 | 65 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 261 | 0.120 |
Why?
| | Prosthesis Design | 3 | 2014 | 327 | 0.120 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 63 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2021 | 1991 | 0.120 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 88 | 0.120 |
Why?
| | Drug Interactions | 1 | 2017 | 410 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1050 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 528 | 0.120 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 430 | 0.120 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 46 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 294 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 744 | 0.120 |
Why?
| | Postoperative Care | 1 | 2017 | 261 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1774 | 0.120 |
Why?
| | Phosphorylation | 3 | 2019 | 1759 | 0.120 |
Why?
| | Tacrolimus | 1 | 2016 | 199 | 0.120 |
Why?
| | Hospital Mortality | 2 | 2009 | 911 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 109 | 0.110 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1266 | 0.110 |
Why?
| | Viscosity | 1 | 2015 | 92 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 57 | 0.110 |
Why?
| | Elastic Modulus | 1 | 2015 | 123 | 0.110 |
Why?
| | Health Status | 1 | 2019 | 792 | 0.110 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 159 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1291 | 0.110 |
Why?
| | Biomarkers | 3 | 2023 | 4149 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 698 | 0.110 |
Why?
| | Attitude to Health | 1 | 2017 | 439 | 0.110 |
Why?
| | Rats | 5 | 2022 | 5647 | 0.110 |
Why?
| | Systole | 1 | 2014 | 189 | 0.110 |
Why?
| | Hip Prosthesis | 1 | 2014 | 46 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2018 | 415 | 0.100 |
Why?
| | Vaccination | 1 | 2022 | 1381 | 0.100 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 63 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1457 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2017 | 546 | 0.100 |
Why?
| | Incidence | 3 | 2019 | 2804 | 0.100 |
Why?
| | Patient Selection | 2 | 2017 | 696 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 123 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2016 | 252 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 871 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2014 | 255 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1178 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2017 | 766 | 0.100 |
Why?
| | Mice, Knockout | 3 | 2025 | 3015 | 0.090 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 36 | 0.090 |
Why?
| | Young Adult | 6 | 2019 | 13209 | 0.090 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 9 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2016 | 712 | 0.090 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1171 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3284 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1129 | 0.090 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 81 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 889 | 0.090 |
Why?
| | Risk Factors | 4 | 2020 | 10388 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 165 | 0.080 |
Why?
| | Connectin | 2 | 2022 | 33 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 900 | 0.080 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 127 | 0.080 |
Why?
| | Endpoint Determination | 2 | 2020 | 77 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2607 | 0.080 |
Why?
| | Stroke | 1 | 2019 | 1120 | 0.080 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 183 | 0.080 |
Why?
| | Pericardial Effusion | 1 | 2010 | 19 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1946 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 201 | 0.080 |
Why?
| | Heart Septum | 1 | 2009 | 28 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 153 | 0.080 |
Why?
| | Anticoagulants | 1 | 2014 | 664 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 1622 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 73 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1459 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2022 | 4193 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1329 | 0.080 |
Why?
| | Exercise | 1 | 2020 | 2057 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 323 | 0.080 |
Why?
| | Ultrasonography | 1 | 2012 | 759 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2022 | 4295 | 0.070 |
Why?
| | Europe | 2 | 2020 | 414 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1719 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2008 | 143 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 358 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5757 | 0.070 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 530 | 0.070 |
Why?
| | Body Temperature | 1 | 2007 | 222 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 413 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 740 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7635 | 0.060 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 284 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2023 | 951 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2426 | 0.060 |
Why?
| | Survivors | 1 | 2009 | 493 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 408 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2017 | 271 | 0.060 |
Why?
| | Benzoxazoles | 1 | 2024 | 19 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2009 | 1587 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 486 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2024 | 99 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 195 | 0.050 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 46 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1916 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 50 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 816 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2085 | 0.050 |
Why?
| | Travel | 1 | 2023 | 130 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 17 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5472 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1313 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 107 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 152 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 98 | 0.050 |
Why?
| | Up-Regulation | 1 | 2025 | 843 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 37 | 0.050 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 53 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 185 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2486 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 159 | 0.050 |
Why?
| | Signal Transduction | 3 | 2021 | 5079 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 317 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 9 | 0.040 |
Why?
| | Adolescent | 4 | 2019 | 21513 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 145 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 28 | 0.040 |
Why?
| | Phenylephrine | 1 | 2021 | 75 | 0.040 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.040 |
Why?
| | Graft Survival | 1 | 2023 | 535 | 0.040 |
Why?
| | Prevalence | 2 | 2018 | 2734 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 64 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 404 | 0.040 |
Why?
| | Chronic Disease | 2 | 2017 | 1793 | 0.040 |
Why?
| | Cardiomegaly | 1 | 2022 | 175 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 165 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 127 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1993 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 1972 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 151 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 157 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2023 | 730 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 59 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 107 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 426 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 46 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 204 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 491 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 30 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 306 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 622 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 898 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 105 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 195 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 195 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 85 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 455 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 230 | 0.040 |
Why?
| | Internship and Residency | 1 | 2009 | 1147 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 317 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 499 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 347 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 443 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 89 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2021 | 696 | 0.030 |
Why?
| | Fibroblasts | 1 | 2022 | 996 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 175 | 0.030 |
Why?
| | Myosins | 1 | 2018 | 135 | 0.030 |
Why?
| | Lysine | 1 | 2019 | 294 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 452 | 0.030 |
Why?
| | Zebrafish | 1 | 2022 | 499 | 0.030 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 12 | 0.030 |
Why?
| | Autoradiography | 1 | 2017 | 78 | 0.030 |
Why?
| | Alleles | 1 | 2020 | 891 | 0.030 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| | Atropine | 1 | 2016 | 23 | 0.030 |
Why?
| | Loperamide | 1 | 2016 | 11 | 0.030 |
Why?
| | Antidiarrheals | 1 | 2016 | 15 | 0.030 |
Why?
| | Papio | 1 | 2017 | 94 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 402 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5778 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 399 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 156 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 413 | 0.030 |
Why?
| | Tissue Donors | 1 | 2019 | 425 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 23 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 65 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 210 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 178 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 628 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 860 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2020 | 468 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 145 | 0.030 |
Why?
| | Actins | 1 | 2018 | 416 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 343 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 248 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 786 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 812 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 956 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1325 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2847 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3566 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 446 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2031 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 176 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 539 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 27 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 726 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2167 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 52 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 573 | 0.030 |
Why?
| | Action Potentials | 1 | 2017 | 493 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1062 | 0.030 |
Why?
| | Warfarin | 1 | 2014 | 154 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 7 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1783 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 467 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 827 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 2016 | 324 | 0.030 |
Why?
| | Creatine | 1 | 2013 | 57 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 261 | 0.020 |
Why?
| | Proteomics | 1 | 2019 | 1111 | 0.020 |
Why?
| | Child, Preschool | 2 | 2019 | 11074 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1287 | 0.020 |
Why?
| | Glutamine | 1 | 2013 | 103 | 0.020 |
Why?
| | Antibodies | 1 | 2014 | 410 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1704 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 152 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 617 | 0.020 |
Why?
| | Chromatin | 1 | 2016 | 519 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1397 | 0.020 |
Why?
| | Dyspnea | 1 | 2014 | 254 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2833 | 0.020 |
Why?
| | Fatigue | 1 | 2014 | 329 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 927 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 305 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3196 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 897 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2071 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 350 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3295 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 1020 | 0.020 |
Why?
| | Child | 2 | 2019 | 21935 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 522 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 746 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9465 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1118 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 343 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|